Drug Trial Radar · NCT07454187
To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Apr 16, 2026
Primary completion
Sep 30, 2027
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Hangzhou Sumgen Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study was to evaluate the safety and tolerability of SG2918 in patients with relapsed/refractory multiple myeloma.
Conditions
- Relapsed/Refractory Multiple Myeloma
Interventions
SG2918Drug
The study adopts a "3+3" dosing escalation approach. Initially, three dose groups are set, namely 1.5mg/kg, 1.8mg/kg, and 2mg/kg. The SG2918 will be administrated by intravenous infusion every 3 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events(AEs )Time frame: From time Day1 of Cycle1 until 30 days after last dose of SG2918
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
The First Affiliated Hospital Of Soochow University
Suzhou, Jiangsu, China · Recruiting
The Second Affiliated Hospital Of Xi an Jiaotong University (Xibei Hospital)
Xi’an, Shanxi, China · Recruiting
The Second Affiliated Hospital Zhejiang University School Of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.